| Name | Title | Contact Details |
|---|---|---|
Pamela Hassen |
Chief Marketing Officer | Profile |
Pamela Hassen |
Chief Marketing Officer | Profile |
Amanda Diamond |
Talent Acquisition Specialist | Profile |
Glen Oaks is a New London, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Onsite Partners, Inc. is a holding company of behavioral services organizations: Onsite Workshops, Milestones, and Onsite at The Oaks. The Onsite family of brands provides services to thousands of clients annually from the United States and Europe, through in-person and virtual settings. Through these companies, Onsite curates transformational emotional health experiences that combine some of the best therapeutic and clinical minds in the country with its signature healing hospitality. Recently Onsite launched a series of virtual emotional health courses and will be expanding this platform in 2021. Onsite offers experiential group programs, counseling intensives, digital courses, and innovative residential trauma treatment that bolster empathy, self-awareness, compassion, and resilience. Onsite`s mission is to change lives through enhanced emotional health. Onsite`s work has been featured on 20/20, Good Morning America, New York Times, Wall Street Journal, Marie Claire, People, Dr. Phil Show, and The Doctors.
Boys Town National Research Hospital is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Commonwealth Diagnostics International (CDI), Inc., was founded on the principle that preventative healthcare, including early detection and diagnosis of disease, results in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Operating out of a newly constructed laboratory in Salem, MA, CDI is an international diagnostic service provider specializing in innovative diagnostic products that assist physicians and patients with the diagnosis and management of some of the world`s most common sources of digestive distress and functional gastrointestinal disorders, including: hydrogen (H2)/methane (CH4) breath testing for Small Intestinal Bacterial Overgrowth (SIBO) and carbohydrate malabsorption, IBSchek™ for IBS-D/M; and AbStats™, an easy-to-use, noninvasive, and reliable digestive telemetry and sensory system. CDI focuses on creating customized operational solutions to diagnostic technologies that drive accessibility and simplicity in lieu of outdated, expensive, invasive, and inaccessible diagnostic modalities. CDI`s entire portfolio of tests can be utilized either at home or with one simple trip to the physician. CDI`s laboratory specializes in customized gas chromatography, ELISA, and isotope-ratio mass spectrometry solutions.
Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.